Hannah Jennifer, Rodziewicz Mia, Mehta Puja, Heenan Kerri-Marie, Ball Elizabeth, Barratt Shaney, Carty Sara, Conway Richard, Cotton Caroline V, Cox Sarah, Crawshaw Anjali, Dawson Julie, Desai Sujal, Fahim Ahmed, Fielding Carol, Garton Mark, George Peter, Gunawardena Harsha, Kelly Clive, Khan Fasihul, Koduri Gouri, Morris Helen, Naqvi Marium, Perry Elizabeth, Riddell Claire, Sieiro Santos Cristiana, Spencer Lisa G, Chaudhuri Nazia, Nisar Muhammad K
Academic Rheumatology, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Centre for Musculoskeletal Research, University of Manchester, Manchester, UK.
Rheumatol Adv Pract. 2024 Apr 18;8(2):rkae056. doi: 10.1093/rap/rkae056. eCollection 2024.
Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.
间质性肺疾病（ILD）是许多系统性自身免疫性风湿病（SARDs）的一种重要并发症，尽管其临床表现、严重程度和预后在个体之间可能有很大差异。尽管ILD很常见，但对于这一多样群体中ILD的筛查、诊断和管理问题，尚无具体指南。美国风湿病学会（ACR）和欧洲抗风湿病联盟（EULAR）的指南值得期待，但需要有考虑英国国家医疗服务体系框架、当地许可和资助策略的英国特定指南。本文概述了由指南工作组制定的英国风湿病学会关于SARD-ILD诊断和管理指南的预期范围。它特别确定了要考虑的SARDs，以及将进行系统评价的总体原则。将根据最新可得证据形成专家共识，以纳入最终指南。需要解决的关键问题包括ILD筛查建议、确定监测方法和频率以及药物和非药物管理。该指南将根据《制定临床指南：英国风湿病学会方案第5.1版》中概述的方法和流程来制定。
